You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 290 No. 18, November 12, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (62)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Surgical Interventions
 •Orthopedic Surgery
 •Randomized Controlled Trial
 •Pain
 •Alert me on articles by topic

Effects of Perioperative Administration of a Selective Cyclooxygenase 2 Inhibitor on Pain Management and Recovery of Function After Knee Replacement

A Randomized Controlled Trial

Asokumar Buvanendran, MD; Jeffrey S. Kroin, PhD; Kenneth J. Tuman, MD; Timothy R. Lubenow, MD; Dalia Elmofty, MD; Mario Moric, PhD; Aaron G. Rosenberg, MD

JAMA. 2003;290:2411-2418.

Context  Controlling postoperative pain after knee replacement while reducing opiod-induced adverse effects and improving outcomes remains an important challenge.

Objective  To assess the effect of combined preoperative and postoperative administration of a selective inhibitor of cyclooxygenase 2 on opioid consumption and outcomes after total knee arthroplasty (TKA).

Design, Setting, and Patients  Randomized, placebo-controlled, double-blind trial conducted June 2001 through September 2002, enrolling 70 patients aged 40 to 77 years and undergoing TKA at a university hospital in the United States.

Interventions  Patients were randomly assigned to receive 50 mg of oral rofecoxib at 24 hours and at 1 to 2 hours before TKA, 50 mg daily for 5 days postoperatively, and 25 mg daily for another 8 days, or matching placebo at the same times.

Main Outcome Measures  Postoperative outcomes including postsurgical analgesic consumption and pain scores achieved, nausea and vomiting, joint range of motion, sleep disturbance, patient satisfaction with analgesia, and hematologic and coagulation parameters.

Results  Total epidural analgesic consumption and in-hospital opioid consumption were less in the group receiving rofecoxib compared with the group receiving placebo (P<.05). Median pain score (visual analog scale [VAS], 0-10) achieved for the knee was lower in the rofecoxib group compared with the placebo group during hospital stay (2.2 [interquartile range {IQR}, 1.4-3.2] vs 3.5 [IQR, 2.7-4.3], P<.001) and 1 week after discharge (2.6 [IQR, 1.4-3.5] vs 3.7 [IQR, 2.9-4.7], P = .03). There was less postoperative vomiting in the rofecoxib group (6%) compared with the placebo group (26%) (P = .047), as well as a decrease in sleep disturbance compared with the placebo group on the night of surgery (P = .006) and on the first (P = .047) and second (P<.001) days postoperatively. Knee flexion was increased in the rofecoxib group compared with the placebo group at discharge (active flexion: mean [SD], 84.2° [11.1°] vs 73.2° [13.6°], P = .03; passive flexion: 90.5° [6.8°] vs 81.8° [13.4°], P = .05) and at 1 month postoperatively (109.3° [8.5°] vs 100.8° [11.8°], P = .01), with shorter time in physical therapy to achieve effective joint range of motion. The rofecoxib group was more satisfied with analgesia and anesthesia at discharge compared with the placebo group (median satisfaction score, 4.3 [IQR, 3.0-4.7] vs 3.3 [IQR, 2.3-4.3], respectively; P = .03), and the differences persisted at 2-week and at 1-month follow-up. There was no intergroup difference in surgical blood loss (P>.05 for both intraoperative and postoperative blood loss).

Conclusion  Perioperative use of an inhibitor of cyclooxygenase 2 is an effective component of multimodal analgesia that reduces opioid consumption, pain, vomiting, and sleep disturbance, with improved knee range of motion after TKA.


Author Affiliations: Departments of Anesthesiology (Drs Buvanendran, Kroin, Tuman, Lubenow, Elmofty, and Moric) and Orthopedic Surgery (Dr Rosenberg), Rush Medical College at Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Prospective Randomized Trial on the Role of Perioperative Celecoxib Administration for Total Knee Arthroplasty: Improving Clinical Outcomes
Reuben et al.
Anesth. Analg. 2008;106:1258-1264.
ABSTRACT | FULL TEXT  

Perioperative Versus Postoperative Celecoxib on Patient Outcomes After Major Plastic Surgery Procedures
Sun et al.
Anesth. Analg. 2008;106:950-958.
ABSTRACT | FULL TEXT  

Preventive effects of perioperative parecoxib on post-discectomy pain
Riest et al.
Br J Anaesth 2008;100:256-262.
ABSTRACT | FULL TEXT  

Minimally Invasive Hip Arthroplasty: What Role Does Patient Preconditioning Play?
Pour et al.
JBJS 2007;89:1920-1927.
ABSTRACT | FULL TEXT  

Preventing the Development of Chronic Pain After Orthopaedic Surgery with Preventive Multimodal Analgesic Techniques
Reuben and Buvanendran
JBJS 2007;89:1343-1358.
ABSTRACT | FULL TEXT  

Effect of short-term postoperative celecoxib administration on patient outcome after outpatient laparoscopic surgery: [Effet de l'administration postoperatoire a court terme de celecoxib sur l'evolution des patients apres une chirurgie par laparoscopie sans hospitalisation]
White et al.
Canadian J. Anesthesia 2007;54:342-348.
ABSTRACT | FULL TEXT  

COX-2 inhibitors in sports medicine: utility and controversy
Buvanendran and Reuben
Br. J. Sports. Med. 2006;40:895-896.
FULL TEXT  

Low-Intensity Pulsed Ultrasound Accelerates and a Nonsteroidal Anti-inflammatory Drug Delays Knee Ligament Healing
Warden et al.
Am J Sports Med 2006;34:1094-1102.
ABSTRACT | FULL TEXT  

Gabapentin: An Alternative to the Cyclooxygenase-2 Inhibitors for Perioperative Pain Management
Turan et al.
Anesth. Analg. 2006;102:175-181.
ABSTRACT | FULL TEXT  

Postoperative Nausea and Vomiting Are Strongly Influenced by Postoperative Opioid Use in a Dose-Related Manner
Roberts et al.
Anesth. Analg. 2005;101:1343-1348.
ABSTRACT | FULL TEXT  

The Changing Role of Non-Opioid Analgesic Techniques in the Management of Postoperative Pain
White
Anesth. Analg. 2005;101:S5-22.
ABSTRACT | FULL TEXT  

Nonsteroidal Antiinflammatory Drugs: A Review
Curry et al.
Journal of the American Animal Hospital Association 2005;41:298-309.
ABSTRACT | FULL TEXT  

Influence of anaesthetic and analgesic techniques on outcome after surgery
Bonnet and Marret
Br J Anaesth 2005;95:52-58.
ABSTRACT | FULL TEXT  

Changing Role of COX-2 Inhibitors in the Perioperative Period: Is Parecoxib Really the Answer?
White
Anesth. Analg. 2005;100:1306-1308.
FULL TEXT  

Cerebrospinal Fluid and Plasma Pharmacokinetics of the Cyclooxygenase 2 Inhibitor Rofecoxib in Humans: Single and Multiple Oral Drug Administration
Buvanendran et al.
Anesth. Analg. 2005;100:1320-1324.
ABSTRACT | FULL TEXT  

Peripheral Nerve Blocks for Postoperative Pain Relief After Total Knee Replacement: More Questions Than Answers
Ben-David and Chelly
Anesth. Analg. 2005;100:1547-1548.
FULL TEXT  

Acute Pain Following Musculoskeletal Injuries and Orthopaedic Surgery. Mechanisms and Management
Ekman and Koman
JBJS 2004;86:1316-1327.
FULL TEXT  

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
WARNER and MITCHELL
FASEB J. 2004;18:790-804.
ABSTRACT | FULL TEXT  

Painkillers before knee surgery improve outcomes
Tanne
BMJ 2003;327:1185-1185.
FULL TEXT  

Pain Management
DeAngelis
JAMA 2003;290:2480-2481.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.